Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Raloxifene Hydrochloride

Known as: Raloxifene Hydrochloride [Chemical/Ingredient], (6-Hydroxy-2-(4-hydroxyphenyl)benzo(b)thien-3-yl)(4-(2-(1-piperidinyl)ethoxy)phenyl)methanone Hydrochloride, Raloxifene HCl 
The hydrochloride salt form of raloxifene, a selective benzothiophene estrogen receptor modulator (SERM) with lipid lowering effects and activity… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2006
Highly Cited
2006
CONTEXT Tamoxifen is approved for the reduction of breast cancer risk, and raloxifene has demonstrated a reduced risk of breast… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
Review
2005
Review
2005
BACKGROUND Quinquennial overviews (1985-2000) of the randomised trials in early breast cancer have assessed the 5 year and 10… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Highly Cited
2002
Highly Cited
2002
Selective estrogen receptor modulators (SERMs) mimic estrogen action in certain tissues while opposing it in others. The… Expand
Highly Cited
2000
Highly Cited
2000
Raloxifene is a selective estrogen receptor modulator that has been shown to prevent bone loss in postmenopausal women. Whether… Expand
Highly Cited
1999
Highly Cited
1999
CONTEXT Raloxifene hydrochloride, a selective estrogen receptor modulator, prevents bone loss in postmenopausal women, but… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
Review
1999
Review
1999
CONTEXT Raloxifene hydrochloride is a selective estrogen receptor modulator that has antiestrogenic effects on breast and… Expand
Highly Cited
1999
Highly Cited
1999
Oestrogens exert their physiological effects through two receptor subtypes. Here we report the three‐dimensional structure of the… Expand
Highly Cited
1997
Highly Cited
1997
BACKGROUND Long-term estrogen therapy can reduce the risk of osteoporotic fracture and cardiovascular disease in postmenopausal… Expand
Highly Cited
1997
Highly Cited
1997
The transactivation properties of the two estrogen receptors, ERalpha and ERbeta, were examined with different ligands in the… Expand
Review
1993
Review
1993
Medical practice is constantly changing. The rate of change is accelerating, and physicians can be forgiven if they often find it… Expand
  • table 1
  • table 2